Aprepitant is indicated for:
Irrespective of gender only Adults (18 years old or older)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adolescents (12 years - 18 years old)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adolescents from the age of 12.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Aprepitant is contraindicated in the following cases:
Co-administration with pimozide, terfenadine, astemizole or cisapride is contraindicated.